---
title: "Cardiovascular Trial Site Selection Criteria 2026 — Sponsor Playbook | Amavita Research"
url: https://md.amavitaresearch.com/blog/cardiovascular-trial-site-selection-criteria-2026
canonical: https://www.amavitaresearch.com/blog/cardiovascular-trial-site-selection-criteria-2026
schema_type: Article
last_updated: 2026-05-13
---

# Cardiovascular Trial Site Selection Criteria 2026

A sponsor playbook for choosing cardiovascular clinical trial sites in 2026, written for clinical operations leaders, medical directors, and sponsor site-selection committees.

## Why site selection drives trial economics

In cardiovascular trials, the wrong site selection produces three failure modes: (1) under-enrollment that extends the study and forces budget overruns, (2) PI turnover mid-study that risks data integrity, and (3) competing trials within the same network that cannibalize the screening funnel. The 2026 site landscape is more consolidated than ever — most commercial U.S. sites are inside private-equity-backed networks — and sponsors need a structured framework to compare independent investigator-led sites, academic medical centers, and multi-site network sites side-by-side.

## The 10 criteria that matter

1. **PI continuity** — Is the named PI a practicing cardiologist at the site, or a part-time/contracted PI? PI turnover during a multi-year cardiovascular trial is a leading source of protocol deviations.
2. **Patient flow source** — Does the site recruit from an in-network cardiology practice (walk-in flow) or from a database (advertising-driven)?
3. **Subspecialty depth** — Does the site have the specific cardiology subspecialist your protocol requires (EP for AFib, interventional for PCI, structural heart for TAVR)?
4. **Trial-cohort competition** — Is the site running competing trials in the same indication? In multi-site networks, this is common and erodes screening yield.
5. **Contract execution speed** — How long from first draft to fully executed CTA? Independent sites: 5–8 weeks. AMCs: 16–36 weeks. Networks: variable.
6. **Cost structure** — F&A overhead at AMCs (25–60%), MSO carve-outs at PE-backed networks, vs. no overhead at independent sites.
7. **Decision authority** — Single-PI sites make site-level decisions in days. MSO-governed sites require central sign-off.
8. **Quality history** — IAOCR GCSA certification, FDA Form 483 history, SCRS membership.
9. **Hybrid US + Latin America design support** — Does the site offer integrated cross-border designs for Phase 1 / first-in-human protocols?
10. **Bilingual screening capability** — In multi-ethnic markets like Miami, screening in the patient's preferred language directly affects enrollment yield.

## How Amavita Research scores on each criterion

- PI continuity: Same PI from site selection to close-out; PI is co-owner of amavita Heart and Vascular Health®
- Patient flow: Walk-in cardiology practice, screened in real time during routine visits
- Subspecialty depth: Triple-board-certified EP, Harvard-trained interventional cardiologist, TAVR-pioneer structural heart consultant
- Trial-cohort competition: No same-indication competitors enrolled without sponsor approval
- Contract execution: 5–8 weeks for qualified trial types
- Cost structure: 20–30% lower than PE-backed Miami networks; no MSO carve-out
- Decision authority: Single PI per protocol; site-level decisions
- Quality history: IAOCR GCSA-certified, zero FDA 483 findings, SCRS member, ICH-GCP E6(R3)
- Hybrid designs: Integrated via sister organization bioaccess® (Latin America CRO)
- Bilingual: English / Spanish / Haitian Creole / Portuguese

## Decision framework

Use this question-tree:

1. Does the protocol require a specific subspecialist (EP, structural heart, interventional)? If yes, eliminate sites without that subspecialist on staff.
2. Is contract execution speed a constraint (e.g., competitive enrollment race)? If yes, favor independent investigator-led sites or networks with proven fast-track CTA processes.
3. Is F&A overhead a budget killer? If yes, eliminate AMCs unless their specific population is required.
4. Is patient cohort competition a known risk in the indication? If yes, prefer single-site or exclusive arrangements over multi-site networks.
5. Is a Latin America arm planned? If yes, consider integrated cross-border designs.

## Discussion contact

- Sponsor contact: https://www.amavitaresearch.com/contact-sponsor
- Site capabilities: https://www.amavitaresearch.com/capabilities
- Trial services: https://www.amavitaresearch.com/trial-services
- Comparison: vs. CRO-owned/PE-backed networks — https://www.amavitaresearch.com/compare/amavita-vs-cro-owned-sites
- Comparison: vs. academic medical centers — https://www.amavitaresearch.com/compare/amavita-vs-academic-medical-center-sites